top of page
QIMR Berghofer Engages with Qubigen to Advance AI-Driven Research in Cancer Pathways
Qubigen is pleased to announce the signing of an agreement with QIMR Berghofer , one of Australia’s leading medical research institutes. The agreement establishes a framework to accelerate the development of novel drug candidates targeting tumorigenesis and cancer progression. By combining Qubigen’s computational modelling and quantum chemistry capabilities with QIMR Berghofer’s deep expertise in translational cancer biology, this partnership aims to illuminate new therapeuti
Nov 19, 20252 min read
Federated AI Can’t Be Ignored - How Qubigen is Doing it Differently
At Qubigen, we do something fundamentally different: we build AI Engines for drug design using our secure Federated AI Drug Design platform (FedAIDD). The platform allows our clients to generate truly novel compounds, without their data ever leaving its server. Qubigen’s FedAIDD can also predict reaction pathways and optimize for desired ADME-T properties, ultimately saving on med-chem costs. Our mission is to unlock the full potential of pharmaceutical data without compromi
Nov 18, 20255 min read
Qubigen to Present at WEHI Divisional Seminar Program on 20 Nov 2025
Qubigen is pleased to announce that its CEO, Dr Jonathan Hall, and its Chief Information Officer, A/Prof Dr Jun Zeng, will be presenting at the Walter and Eliza Hall Institute of Medical Research (WEHI) Divisional Seminar Program . Hosted by Professor Guillaume Lessene, the seminar will explain how Qubigen’s proprietary Federated AI Platform (FedAIDD) is enabling a new paradigm in collaborative drug design. Date Thursday, 20 November 2025 Time 10:45 to 11:45 AM Location WEH
Nov 14, 20252 min read
bottom of page